At Virogentics, we are committed to developing safe and effective treatments for viral infections. Our IPF Technology has shown promising results in preclinical studies, and we are working hard to bring our treatments to patients in need. Contact us to learn more about our mission and how you can help.

​

Virogentics, Inc., a drug development biotech company, is managed by Diana Zhabilov as Chairman and CEO, Harry Zhabilov as its CSO and Director, and Dr. Lachezar Ivanov PhD as the company's representative in Bulgaria. Since 2021, the Virogentics’ research and development team have made great strides with the GMP production of ITV-1 as well as the FDA registered nutraceutical supplement IPF Immune®. Virogentics, Inc. is focused  in advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a solution of Inactivated Pepsin Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown to modulate the immune system.

The company has also filed a new utility application for Immune Therapeutic Proteins (ITP) and their applications.